Introduction: ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information.
View Article and Find Full Text PDFAim: To evaluate whether initiation of anti-hypertensive treatment with methyldopa affects fetal hemodynamics in women with pregestational diabetes.
Methods: Prospective study of unselected singleton pregnant women with diabetes (seven type 1 and two type 2 diabetes), normal blood pressure and kidney function at pregnancy booking. Methyldopa treatment was initiated at blood pressure >135/85 mmHg and/or urinary albumin excretion (UAE) >300 mg/g creatinine.
Introduction: The objective of this study was to evaluate the implementation of the present Danish selective screening strategy for possible hepatitis B infection in pregnant women who themselves or whose partners originate from medium- or high-endemic hepatitis B areas of the world. We also investigated whether children of hepatitis B carriers were treated with immunoglobulin and vaccination.
Materials And Methods: We did a retrospective study of 1,924 birth notification forms of women who had delivered between 1 January and 30 June 2000 in Frederiksborg County, Denmark.
Objective: To evaluate the perinatal outcome and the frequency of maternal complications in pregnancies of women with type 2 diabetes during 1996-2001.
Research Design And Methods: Medical records of 61 consecutive singleton pregnancies in women with type 2 diabetes from 1996 to 2001 were studied. Pregnancy outcome was compared with that of pregnant women with type 1 diabetes during 1996-2000, the background population, and pregnant women with type 2 diabetes during 1980-1992 from the same department.